Isatuximab for red blood cell recovery after stem cell transplant
Treatments studied
Part of Blood & lymphatic clinical trials.
This study tests a drug called isatuximab for people who still need red blood cell transfusions after a stem cell transplant from a donor with a different blood type. The drug is an antibody that may help your body start making red blood cells again.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 15 years or older.
- You have had a stem cell transplant from a donor with a different blood type (major mismatch).
- You still need red blood cell transfusions 60 days or more after the transplant, because your body isn't making enough red blood cells.
- Your original blood disease has not come back.
- You are not taking erythropoietin, certain other treatments, or have certain infections (like HIV or active hepatitis).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a stem cell transplant using a milder conditioning regimen and a drug called post-transplant cyclophosphamide to treat severe aplastic anemia and other acquired bone marrow failure conditions. The goal is to help patients achieve a functioning donor bone marrow with fewer side effects.
This study tests a new antibody drug (anti-CD38) for people with severe aplastic anemia that has not responded to or has come back after standard treatments. The goal is to see if this drug can help improve blood counts when other options have failed.
This trial studies a stem cell transplant approach for children with sickle cell disease, using a sibling donor whose blood type is not compatible. It aims to see if this transplant method can safely reduce serious sickle cell complications.
This trial compares two drugs, romiplostim and rhTPO, to help increase platelet counts after a stem cell transplant in people with MDS or aplastic anemia. The goal is to see which drug works better at reducing the need for platelet transfusions.
This trial tests if romiplostim, a drug that helps the body make platelets, can speed up platelet recovery after a special type of stem cell transplant from a half-matched donor. It may help reduce bleeding risk during the recovery period.
This Phase 2 study tests a specialized stem cell transplant that removes certain immune “T-cell” receptors to help treat blood cancers like acute leukemia. It may help your body rebuild a healthier immune system after high-dose treatment.
Hear when a new Immunological Pure Red Cell Aplasia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.